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Background: Adverse reactions to metal debris (ARMD) have resulted in the high short-term failure rates observed with
metal-on-metal hip replacements. ARMD has recently been reported in non-metal-on-metal total hip replacements (non-
MoM THRs) in a number of small cohort studies. However the true magnitude of this complication in non-MoM THRs
remains unknown. We used a nationwide database to determine the risk of ARMD revision in all non-MoM THRs, and
compared patient and surgical factors associated with ARMD revision between non-MoM and MoM hips.
Methods: We performed a retrospective observational study using data from the National Joint Registry for England,
Wales, Northern Ireland and the Isle of Man. All primary hip replacements undergoing revision surgery for ARMD were
included (n= 3,340). ARMD revision risk in non-MoM THRs was compared between different commonly implanted
bearing surfaces and femoral head sizes (Chi-squared test). Differences in patient and surgical factors between non-MoM
hips and MoM hips revised for ARMD were also analysed (Chi-squared test and unpaired t-test).
Results: Of all ARMD revisions, 7.5% (n = 249) had non-MoM bearing surfaces. The relative risk of ARMD revision was 2.35
times (95% CI 1.76–3.11) higher in ceramic-on-ceramic bearings compared with hard-on-soft bearings (0.055 vs. 0.024%;
p < 0.001), and 2.80 times (95% CI 1.74–4.36) higher in 36 mm metal-on-polyethylene bearings compared to 28 mm and
32 mm metal-on-polyethylene bearings (0.058 vs. 0.021%; p < 0.001). ARMD revisions were performed earlier in non-MoM
hips compared to MoM hips (mean 3.6-years vs. 5.6-years; p < 0.0001). Non-MoM hips had more abnormal findings at
revision (63.1 vs. 35.7%; p< 0.001), and more intra-operative adverse events (6.4 vs. 1.6%; p < 0.001) compared to MoM
hips.
Conclusions: Although the overall risk of ARMD revision surgery in non-MoM THRs appears low, this risk is increasing,
and is significantly higher in ceramic-on-ceramic THRs and 36 mm metal-on-polyethylene THRs. ARMD may therefore
represent a significant clinical problem in non-MoM THRs.
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Total hip replacement (THR) is the most successful sur-
gical procedure for treating patients with hip arthritis
[1]. 332,000 THRs are performed annually in the United
States [2] with numbers expected to increase rapidly
[3, 4]. Revision surgery for failed THR remains a sig-
nificant problem, especially in young patients with
high activity levels, with the future revision burden
also expected to substantially increase [3–6].
Modifications were made to traditional THRs with
metal-on-polyethylene bearing surfaces in an attempt
to improve implant longevity and patient function.
These included newer bearing surfaces with larger
femoral head sizes, which aimed to reduce bearing wear
and dislocation risk, whilst increasing hip movement. Fur-
thermore, modular implants were an attractive concept to
surgeons as they provided more flexibility in terms of help-
ing to restore patient anatomy and optimising hip biomech-
anics [7]. As a result large-diameter metal-on-metal (MoM)
bearing surfaces became popular with approximately 1.5
million of these designs implanted worldwide in young and
active patients. However, MoM hips experienced high
short-term failure rates [8, 9] with many revisions per-
formed for adverse reactions to metal debris (ARMD)
[10, 11]. The aetiology of ARMD remains incompletely
understood. Initially excessive bearing wear was consid-
ered to be responsible, but more recently wear and cor-
rosion at modular THR junctions has been implicated
[12–14]. ARMD lesions are often invasive and destruc-
tive [10, 11], with poor outcomes reported following re-
vision surgery [15]. Worldwide regulatory authorities
therefore recommend regular follow-up for MoM hip
patients [16, 17].
The three main bearing surfaces currently used in
THR are metal-on-polyethylene, ceramic-on-ceramic,
and ceramic-on-polyethylene [18, 19]. Recently ARMD
requiring revision surgery has been observed in non-
MoM THRs [20–24]. Small studies have reported be-
tween 7 and 27 ARMD revisions in non-MoM THRs,
which mainly occurred in newer implant designs with
large femoral heads [20–24]. One study estimated that
0.25% of consecutive non-MoM THRs (12 of 4813) im-
planted at their centre subsequently required revision
for ARMD [23]. However, the true risk of revision sur-
gery for ARMD in non-MoM THRs remains unknown.
The National Joint Registry (NJR) for England, Wales,
Northern Ireland and the Isle of Man was established in
2003 to identify poorly performing implants early, and
represents the world’s largest arthroplasty registry [18].
We assessed all hip replacements undergoing revision
surgery for ARMD recorded in the NJR. The study aims
were to: (1) determine the risk of ARMD revision
surgery in all non-MoM hip replacements, and (2) com-
pare patient and surgical factors associated with ARMDrevision between non-MoM hip replacements and MoM
hip replacements.
Methods
We performed a retrospective observational study using
data from the NJR for England, Wales, Northern Ireland
and the Isle of Man. The NJR contains details of all pri-
mary and revision hip replacement procedures per-
formed since April 2003. The present study was based
on a subgroup of 3,433 hip replacements known to have
required revision surgery for ARMD up until the 18th
November 2015. At the time this dataset was acquired
the NJR had recorded a total of 889,340 primary hip re-
placement procedures.
Numerous terms have been used to describe abnormal
destructive reactions related to MoM hip replacements that
require revision surgery. These include ARMD [11, 14],
pseudotumour [10], aseptic lymphocytic vasculitis-
associated lesions [25], and adverse local tissue reaction
[26]. These terms are often used interchangeably to de-
scribe the same process. In June 2008, the NJR first in-
troduced the term ARMD for surgeons to select as an
indication for revision surgery, given ARMD is considered
the most inclusive term for these abnormal reactions
[11, 14]. The present study includes all primary hip replace-
ments revised for ARMD between 1st June 2008 and 18th
November 2015, which have been recorded in the NJR.
By using unique patient identifiers all 3,433 revision pro-
cedures for ARMD could be linked to the primary hip re-
placement procedure. For both the primary and revision
procedures the NJR collects data on patient demographics
(age, gender, body mass index, American Society of Anes-
thesiologists (ASA) grade, indication for surgery, venous
thromboembolism prophylaxis), surgery performed (sur-
geon grade, surgical approach, details of components im-
planted including the bearing surface, component size, and
implant fixation), and intra-operative adverse surgical
events (calcar crack; pelvic and/or femoral shaft penetra-
tion; trochanteric and/or femoral shaft fracture; other),
which were all available for analysis in the present study. In
addition, NJR data on revision procedures provided detailed
information on intra-operative findings, including reason(s)
for revision surgery. After linking primary and revision pro-
cedures the bearing surface implanted at the primary sur-
gery could not be clearly identified in 93 cases. These were
excluded, leaving 3,340 hip revisions performed for ARMD
in the final study cohort for analysis. Conventional methods
for describing bearing surfaces were used, for example
metal-on-polyethylene represents a metal femoral head ar-
ticulating with a polyethylene liner or socket.
Statistical analysis
The cohort was divided into two groups based on whether
the primary hip replacement bearing surface was non-
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THRs and hip resurfacings. Subsequent analyses were sepa-
rated into two distinct parts to reflect the study aims.
Risk of ARMD revision surgery in non-MoM hip
replacements
To calculate the risk of ARMD revision surgery, observa-
tional data for all hip replacements revised for ARMD as
recorded in the NJR were available as the numerator.
Complete clinical data on all hip replacements not under-
going revision surgery were not available. For the denom-
inator, data from the NJR were provided on the total
number of primary hip replacements performed as a
whole, and for different bearing surfaces and femoral head
sizes. Hence it was possible to calculate the risk of ARMD
revision surgery for the whole NJR population, and for
each bearing surface and femoral head size subgroup. The
relative risk of ARMD revision between different non-
MoM bearing surfaces and femoral head sizes were com-
pared using the Chi-squared test with Yates’ correction.
Comparison of patient and surgical factors associated with
ARMD revision between non-MoM and MoM hip
replacements
Patients were selected for this study based on their final
outcome, i.e., revision of a primary hip replacement for
ARMD. Patient and surgical factors (for both the primary
hip replacement and the revision surgery for ARMD) were
subsequently compared between non-MoM hip replace-
ments (cases) and MoM hip replacements (controls). Data
from all numerical co-variates were normally distributed
and compared using unpaired t-tests, with categorical data
assessed using either the Chi-squared test with Yates’ cor-
rection or Fisher’s exact test. Time to ARMD revision sur-
gery was also assessed using the Kaplan-Meier method,
with a univariate Cox proportional hazards model used to
compare time to revision by type of primary bearing sur-
face. As the analysis only included observational data on
hip replacements revised for ARMD, the different primary
bearing surface groups in this Cox model all reached a
survival probability of zero. Multivariable logistic regression
modeling was used to assess the effect of patient
demographics (age, gender, ASA grade, indication for
primary surgery, time to revision surgery) on the bin-
ary outcome variable (whether an ARMD revision was
performed in a non-MoM or MoM hip replacement).
Surgical factors (such as surgical approach, compo-
nent size, and implant fixation) were not included in
the logistic regression models given these factors are
almost completely determined by the initial decision
to perform either a primary non-MoM or MoM hip
replacement, hence these surgical factors are part of
the causal pathway [9]. When assessing patient demo-
graphics in the logistic regression models, linearity ofcontinuous predictors was assessed using fractional
polynomials with data grouped if affects were non-
linear. All analyses were performed using Stata Version
13.1 (Lakeway Drive, Texas, USA) with 95% confidence
intervals (CIs) provided for all estimates.Results
Risk of ARMD revision surgery
Of 3,340 primary hip replacements undergoing revision
surgery for ARMD, 249 (7.5%) had non-MoM bearing
surfaces with the remaining 3,091 (92.5%) hips having
MoM bearings (Fig. 1).
During the study period a total of 873,188 primary hip
replacements were recorded in the NJR where the pri-
mary bearing surface could be correctly identified. The
risk of ARMD revision surgery in all implanted primary
hip replacements was 0.38% (3,340/873,188; 95% CI
0.37–0.40%). The risk of ARMD revision surgery in all
non-MoM hip replacements recorded in the NJR was
0.032% (249/789,397; 95% CI 0.028–0.036%) compared
to 3.7% (3,091/83,791; 95% CI 3.6–3.8%) in MoM hip re-
placements (p < 0.001).
When non-MoM hip replacements were subdivided by
bearing surface, the risk of ARMD revision surgery by
primary bearing surface was: metal-on-polyethylene
0.024% (125/526,951; 95% CI 0.020–0.028%), ceramic-
on-ceramic 0.055% (75/135,267; 95% CI 0.044–0.070%),
ceramic-on-polyethylene 0.023% (29/124,656; 95% CI
0.016–0.033%), ceramic-on-metal 0.69% (16/2,320; 95%
CI 0.39–1.12%), and metal-on-ceramic 1.97% (4/203;
95% CI 0.54–4.97%).
Although ceramic-on-metal and metal-on-ceramic
bearings had the highest risk of ARMD revision for all
non-MoM bearings, they were implanted in small num-
bers and are no longer used. When these two non-MoM
bearing surfaces were excluded, the risk of ARMD revi-
sion in non-MoM hip replacements was dependent on
bearing surface and femoral head size. The relative risk
of ARMD revision was 2.35 times (95% CI 1.76–3.11)
higher in hard-on-hard (ceramic-on-ceramic) compared
with hard-on-soft bearing surfaces (metal-on-polyethyl-
ene and ceramic-on-polyethylene) (p < 0.001). The rela-
tive risk of ARMD revision was 2.80 times (95% CI
1.74–4.36) higher in 36 mm metal-on-polyethylene bear-
ings compared to 28 mm and 32 mm (28/32 mm)
metal-on-polyethylene bearings (p < 0.001; Table 1). The
risk of ARMD revision was not influenced by femoral
head size in both ceramic-on-ceramic and ceramic-on-
polyethylene bearing surfaces (Table 1). However, the
risk of ARMD revision in both 28/32 mm (0.057%) and
36 mm (0.052%) ceramic-on-ceramic bearings was
similar to 36 mm metal-on-polyethylene bearings
(0.058%).
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Fig. 1 Cumulative number of hip revision procedures performed for ARMD between 2008 and 2015 stratified by the type of primary hip
replacement. ARMD = adverse reactions to metal debris; MoM =metal-on-metal; THR = total hip replacement
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MoM hips subsequently revised for ARMD (Table 2)
Non-MoM hip patients were significantly older (p <
0.0001) with higher ASA grades (p < 0.001) at primary
surgery. Significantly larger femoral head sizes were im-
planted in MoM hips at primary surgery (femoral head
sizes ≥36 mm implanted in 98.6% of MoM hips vs.
38.2% of non-MoM hips; p < 0.001).
Differences at revision surgery between non-MoM and
MoM hips revised for ARMD (Table 3)
Revision for ARMD was performed significantly earlier
in non-MoM hips compared to MoM hips (mean time
from primary to revision surgery 3.6 vs. 5.6 years; p <
0.0001; Fig. 2). Non-MoM hips were significantly more
likely to undergo staged revision procedures than MoM
hips (6.8 vs. 1.8%; p < 0.001), and were significantly more
likely to have other abnormalities at revision (63.1 vs.Table 1 Risk of ARMD revision surgery for the three most commonl
femoral head size
Hip bearing surface Femoral head
size (mm)
Number of hips
implanted
Number of hips
revised for ARMD
R
s
MoP 28 & 32 407,412 85 0
MoP 36 46,258 27 0
CoC 28 & 32 61,937 35 0
CoC 36 67,373 35 0
CoP 28 & 32 96,286 24 0
CoP 36 24,513 5 0
ARMD Adverse reactions to metal debris, CoC Ceramic-on-ceramic, CoP Ceramic-on-35.7%; p < 0.001), including aseptic component loosening
(p < 0.001), osteolysis (p < 0.001), implant malalignment
(p < 0.001), dislocation/subluxation (p < 0.001), fracture
(p = 0.003), and infection (p = 0.001). Significantly more
intra-operative adverse events (including pelvic and/or
femoral shaft penetration/fractures) occurred in non-
MoM hips revised for ARMD compared to MoM hips
(6.4 vs. 1.6%; p < 0.001).
Discussion
Prior to this study it was not known whether ARMD
associated with non-MoM hip replacements represented
a significant clinical problem. Analysis of the world’s
largest arthroplasty database has demonstrated that
although the risk of revision surgery for ARMD in non-
MoM THRs was low, the risk is increasing with one-in-
thirteen ARMD revisions performed in non-MoM hip
replacements. Furthermore, the risk of ARMD revisiony implanted primary hip replacement bearing surfaces by
isk of ARMD revision
urgery (%) (95% CI)
Relative risk (95% CI) of
ARMD revision with 36 mm
head size (vs. 28/32 mm)
p-value (36 mm vs.
28/32 mm for same
bearing surface)
.021 (0.017–0.026) 2.80 (1.74–4.36) <0.001
.058 (0.038–0.085)
.057 (0.039–0.079) 0.92 (0.56–1.51) 0.725
.052 (0.036–0.072)
.025 (0.016–0.037) 0.82 (0.24–2.19) 0.683
.020 (0.007–0.048)
polyethylene, MoP Metal-on-polyethylene, CI Confidence interval
Table 2 Patient and surgical factors relating to the primary hip replacement procedure in all hips subsequently revised for ARMD
Co-variate All ARMD revisions
(n = 3340) (100%)
ARMD revisions in MoM hips
(n = 3091) (92.5%)
ARMD revisions in non-MoM hips
(n = 249) (7.5%)
p-value Odds ratio (95% CI)
Gender
Female vs. male 1,967 (58.89) 1,810 (58.56) 157 (63.05) 0.165 0.87 (0.66–1.14)
Age (in years)a
Mean (SD) 58.8 (10.0) 58.4 (9.8) 63.8 (11.0) <0.0001
< 50 557 (16.68) 534 (17.28) 23 (9.24) <0.001 Ref
50–59 1,113 (33.32) 1,061 (34.33) 52 (20.88) 1.12 (0.67–1.87)
60–69 1,227 (36.74) 1,134 (36.69) 93 (37.35) 1.81 (1.11–2.93)
≥ 70 443 (13.26) 362 (11.71) 81 (32.53) 4.72 (2.86–7.78)
BMI (in kg/m2)b
Mean (SD) 28.3 (4.8) 28.3 (4.9) 28.3 (4.4) 0.978 -
Primary hip design
THR 2,359 (70.63) 2110 (68.3) 249 (100) NA -
HR 981 (29.37) 981 (31.7) 0 (0)
Bearing surface
MoM 3,091 (92.54) 3091 (100) 0 (0) NA -
MoP 125 (3.74) 0 (0) 125 (50.20)
CoC 75 (2.25) 0 (0) 75 (30.12)
CoP 29 (0.87) 0 (0) 29 (11.65)
CoM 16 (0.48) 0 (0) 16 (6.43)
MoC 4 (0.12) 0 (0) 4 (1.61)
Femoral head size (mm)
Mean (SD) 43.0 (6.4) 43.9 (5.7) 32.1 (4.0) <0.0001 -
Range 22.25–60 28–60 22.25–44
Median 44 46 32
Inter-quartile range 36–48 38–48 28–36
≤ 28 143 (4.28) 44 (1.42) 99 (39.76) <0.001
32 55 (1.65) 0 (0) 55 (22.09)
36–42 1,197 (35.84) 1,103 (35.68) 94 (37.75)
44–48 1,373 (41.11) 1,372 (44.39) 1 (0.40)
50–52 449 (13.44) 449 (14.53) 0 (0)
≥ 54 123 (3.68) 123 (3.98) 0 (0)
Cup fixationb
Uncemented 3,285 (98.73) 3,078 (99.96) 207 (83.46) <0.001 -
Cemented 42 (1.26) 1 (0.04) 41 (16.53)
Stem fixation (THR only)b
Uncemented 2,090 (91.15) 1,922 (93.85) 168 (68.57) <0.001 -
Cemented 203 (8.85) 126 (6.15) 77 (31.43)
ASA grade
1 1,228 (36.77) 1,169 (37.82) 59 (23.69) <0.001 Ref
2 1,948 (58.32) 1,776 (57.46) 172 (69.08) 1.61 (1.18–2.20)
3 or above 164 (4.91) 14 (4.72) 18 (7.23) 1.68 (0.95–2.97)
Indication for surgery
Primary OA vs. other 3,139 (93.98) 2,906 (94.01) 233 (93.57) 0.779 0.73 (0.42–1.26)
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Table 2 Patient and surgical factors relating to the primary hip replacement procedure in all hips subsequently revised for ARMD
(Continued)
Surgeon grade
Consultant vs. other 2,909 (87.10) 2,699 (87.32) 210 (84.34) 0.177 -
Complex primary 174 (5.21) 161 (5.21) 13 (5.22) 0.993 -
Surgical approachb
Posterior vs. other 2,241 (69.04) 2,109 (70.23) 132 (54.32) <0.001 -
VTE - chemical
LMWH (+/-other) 1,673 (50.09) 1,524 (49.30) 149 (59.84) <0.001 -
Aspirin only 419 (12.54) 401 (12.97) 18 (7.23)
Other 197 (5.90) 150 (4.85) 47 (18.88)
None 1,051 (31.47) 1,016 (32.87) 35 (14.06)
VTE - mechanical
Any vs. none 2,919 (87.40) 2,690 (87.03) 229 (91.97) 0.024 -
Adverse surgical
eventsc
42 (1.83) 35 (1.68) 7 (3.30) 0.102 -
ARMD Adverse reactions to metal debris, ASA American Society of Anesthesiologists, BMI Body mass index, CoC Ceramic-on-ceramic, CoM Ceramic-on-metal, CoP
Ceramic-on-polyethylene, CI Confidence interval, HR Hip resurfacing, LMWH Low molecular weight heparin, MoC Metal-on-ceramic, MoM Metal-on-metal, MoP
Metal-on-polyethylene, NA Not applicable, OA Osteoarthritis, Ref Reference group, SD Standard deviation, THR Total hip replacement, VTE
Venous thrombo-embolism
Values in brackets are percentages unless otherwise indicated. Statistically significant differences between the two groups (p < 0.05) have been highlighted in
bold text
aAffect of age at primary surgery on outcome was non-linear so variable was grouped
bMissing data for stated number of hips: BMI (n = 2246); surgical approach (n = 94); cup fixation (n = 13); THR stem fixation (n = 66)
cIntra-operative adverse events included: calcar crack; pelvic and/or femoral shaft penetration; trochanteric and/or femoral shaft fracture; other
-Co-variate was not included in multivariable logistic regression model as either it was a surgical factor that is part of the causal pathway, or there was significant
missing data
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and 36 mm metal-on-polyethylene THRs.
Overall risk of revision surgery for ARMD
The observation that 7.5% of all ARMD revisions were
performed in non-MoM THRs is high, especially given
the small number of cases reported worldwide [20–24].
Coupled with the annual increasing trend of ARMD
revisions in non-MoM THRs these observations are
concerning. As only limited reports have been published
[20–24] there is currently a relative lack of awareness
amongst clinicians that ARMD associated with non-
MoM hips represents a significant problem. Therefore
our findings are likely to be influenced by surveillance
bias and the true ARMD revision risk is potentially
underestimated. The number of ARMD revisions per-
formed in MoM hips were also heavily influenced by
surveillance bias given revisions increased considerably
between 2010 and 2013, which reflects widespread rec-
ognition of this problem and the implementation of
regular patient follow-up [16, 17]. If closer surveillance
is deemed necessary for non-MoM THRs [7], the risk of
ARMD revision is expected to increase at a greater rate
than presently.
The risk of ARMD revision in the three commonest
non-MoM bearing surfaces appears low (0.023–0.055%)as this entity is not well recognised and the overall num-
ber of THRs implanted is very large. However, the risk
of ARMD revision in MoM hips in 2015 (3.7%) has in-
creased 25-fold compared to that reported in 2009 (0.15%),
when little was known about ARMD in MoM hips [27].
Although we suspect the risk of ARMD revision in non-
MoM hips will not reach levels observed in MoM hips,
the risk may increase at a similar rate.
ARMD risk by bearing surface and femoral head size
ARMD revisions were performed in all commonly im-
planted non-MoM bearing surfaces and all femoral head
sizes. However, the risk of ARMD revision was 2.35
times higher in ceramic-on-ceramic bearings compared
with hard-on-soft bearings, and 2.80 times higher in
36 mm metal-on-polyethylene bearings compared to
smaller metal-on-polyethylene THRs.
Ceramic-on-ceramic THRs became popular for treat-
ing young and active patients with hip arthritis, espe-
cially since high failure rates associated with MoM
bearings were recognised [18, 19]. Analysis of NJR data
in 2012 observed low all-cause revision rates in large-
diameter ceramic-on-ceramic bearings, therefore the
continued use of ceramic-on-ceramic THRs with large
femoral head sizes was recommended [8]. By contrast,
with regard to the risk of ARMD revision our data
Table 3 Patient and surgical factors relating to the revision hip replacement procedure performed for ARMD
Co-variate All ARMD revisions
(n = 3340) (100%)
ARMD revisions in MoM hips
(n = 3091) (92.5%)
ARMD revisions in non-MoM hips
(n = 249) (7.5%)
p-value Odds ratio
(95% CI)
Gender
Female vs. male 1,967 (58.89) 1,810 (58.56) 157 (63.05) 0.165 0.81 (0.62–1.07)
Age (in years)a
Mean (SD) 64.2 (10.1) 64.0 (10.0) 67.5 (10.9) <0.0001
< 50 271 (8.11) 255 (8.25) 16 (6.43) <0.001 Ref
50–59 712 (21.32) 672 (21.74) 40 (16.06) 0.94 (0.51–1.72)
60–69 1,292 (38.68) 1,214 (39.28) 78 (31.33) 1.17 (0.66–2.06)
≥ 70 1,065 (31.89) 950 (30.73) 115 (46.18) 2.34 (1.33–4.12)
BMI (in kg/m2)b
Mean (SD) 29.0 (5.2) 29.0 (5.2) 28.5 (5.3) 0.285 -
Bilateral ARMD revisions 282 (8.44) 281 (9.09) 1 (0.40) <0.001 -
Time from primary to revision (in years)a
Mean (SD) 5.4 (2.1) 5.6 (2.0) 3.6 (2.9) <0.0001
≤ 5 1,387 (41.53) 1,209 (39.11) 178 (71.49) <0.001 Ref
> 5 1,953 (58.47) 1,882(60.89) 71 (28.51) 0.23 (0.17–0.30)
ASA grade
1 609 (18.23) 569 (18.41) 40 (16.06) 0.012 Ref
2 2,389 (71.53) 2,219 (71.79) 170 (68.27) 1.01 (0.70–1.47)
3 or above 342 (10.24) 303 (9.80) 39 (15.66) 1.70 (1.04–2.78)
VTE - chemical
LMWH (+/-other) 1,798 (53.83) 1,644 (53.19) 154 (61.85) 0.002 -
Aspirin only 92 (2.75) 80 (2.59) 12 (4.82)
Other 1,155 (34.58) 1,093 (35.36) 62 (24.90)
None 295 (8.83) 274 (8.86) 21 (8.43)
VTE - mechanical
Any vs. none 3,189 (95.48) 2,957 (95.66) 232 (93.17) 0.069 -
Surgeon grade
Consultant vs. other 3,201 (95.84) 2,963 (95.86) 238 (95.58) 0.833 -
Surgical approachb
Posterior vs. other 2,691 (81.87) 2,516 (82.55) 175 (73.22) <0.001 -
Revision type
Single stage 3,266 (97.78) 3,034 (98.16) 232 (93.17) <0.001 -
Staged (2 or more) 71 (2.13) 54 (1.75) 17 (6.83)
Excision arthroplasty 3 (0.09) 3 (0.10) 0 (0)
Revision indications/intra-operative findingsc
1 indication 2,080 (62.28) 1,988 (64.32) 92 (36.95) <0.001 -
2 to 6 indications 1,260 (37.72) 1,103 (35.68) 157 (63.05)
ARMD 3340 (100) 3091 (100) 249 (100) NA -
Pain 665 (19.91) 618 (19.99) 47 (18.88) 0.671 -
Aseptic loosening 338 (10.12) 278 (8.99) 60 (24.10) <0.001 -
Osteolysis 255 (7.63) 221 (7.15) 34 (13.65) <0.001 -
Implant malalignment 118 (3.53) 96 (3.11) 22 (8.84) <0.001 -
Other indications/findings 101 (3.02) 98 (3.17) 3 (1.20) 0.084 -
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Table 3 Patient and surgical factors relating to the revision hip replacement procedure performed for ARMD (Continued)
Acetabular component wear 83 (2.49) 46 (1.49) 37 (14.86) <0.001 -
Dislocation/subluxation 67 (2.01) 41 (1.33) 26 (10.44) <0.001 -
Fracture 66 (1.98) 54 (1.75) 12 (4.82) 0.003 -
Infection 43 (1.29) 33 (1.07) 10 (4.02) 0.001 -
Liner dissociation 25 (0.75) 10 (0.32) 15 (6.02) <0.001 -
Implant fracture 18 (0.54) 7 (0.23) 11 (4.42) <0.001 -
Incorrect implant size 17 (0.51) 11 (0.36) 6 (2.41) 0.001 -
Revision procedureb,d
All components revised 1,267 (38.79) 1,202 (39.62) 65 (28.02) <0.001 -
Cup (+/- head/liner/taper) 1,426 (43.66) 1,350 (44.50) 76 (32.76)
Stem (+/- head/liner/taper) 144 (4.41) 107 (3.53) 37 (15.95)
Head/ liner/taper revision only 422 (12.92) 370 (12.20) 52 (22.41)
Femoral head size (mm)b,d
Mean (SD) 34.1 (3.3) 34.1 (3.2) 33.2 (3.7) 0.0003 -
Range 22.25–48 22.25–48 22.25–40
Median 36 36 36
Inter-quartile range 32–36 32–36 32–36
≤ 32 1,180 (37.94) 1,073 (37.09) 107 (49.31) 0.001
36 1,783 (57.33) 1,683 (58.17) 100 (46.08)
> 36 147 (4.73) 137 (4.74) 10 (4.61)
Bearing surfaceb,d
CoP 1,479 (47.6) 1,394 (48.4) 85 (38.1) <0.001 -
CoC 885 (28.5) 841 (29.2) 44 (19.7)
MoP 736 (23.7) 642 (22.3) 94 (42.2)
CoM 3 (0.10) 3 (0.10) 0 (0)
MoM 2 (0.06) 2 (0.07) 0 (0)
MoC 1 (0.03) 1 (0.03) 0 (0)
Cup fixationd
Uncemented 2,355 (87.45) 2,239 (87.74) 116 (82.27) 0.057 -
Cemented 338 (12.55) 313 (12.26) 25 (17.73)
Stem fixationd
Uncemented 867 (61.45) 819 (62.57) 48 (47.06) 0.002 -
Cemented 544 (38.55) 490 (37.43) 54 (52.94)
Bone graft (femoral)d 107 (3.20) 99 (3.20) 8 (3.21) 0.993 -
Bone graft (acetabular)d 650 (19.46) 611 (19.77) 39 (15.66) 0.116 -
Adverse surgical eventsd,e 64 (1.92) 48 (1.55) 16 (6.43) <0.001 -
ARMD Adverse reactions to metal debris, ASA American Society of Anesthesiologists, BMI Body mass index, CoC Ceramic-on-ceramic, CoM Ceramic-on-metal, CoP
Ceramic-on-polyethylene, CI Confidence interval, HR Hip resurfacing, LMWH Low molecular weight heparin, MoC Metal-on-ceramic, MoM Metal-on-metal, MoP
Metal-on-polyethylene, NA Not applicable; Ref Reference group, SD Standard deviation, THR Total hip replacement, VTE Venous thrombo-embolism
Values in brackets are percentages unless otherwise indicated. Statistically significant differences between the two groups (p < 0.05) have been highlighted in
bold text
aAffect of age at revision surgery on outcome, and affect of time to revision surgery on outcome were non-linear so variables were grouped
bMissing data for stated number of hips: BMI (n = 886); surgical approach (n = 53); revision procedure (n = 7); femoral head size (n = 156); bearing surface (n = 160)
cIntra-operative revision findings refer to a problem with one or both hip components (loosening, fracture etc.)
dAll details about the specific revision surgical procedures performed are provided for the 3266 hips (97.8% of the cohort) undergoing single stage revisions.
Therefore details about 74 hip revisions undergoing either 2 or more stages, or excision arthroplasty procedures have not been included
eIntra-operative adverse events included: calcar crack; pelvic and/or femoral shaft penetration; trochanteric and/or femoral shaft fracture; other
- Co-variate was not included in multivariable logistic regression model as either it was a surgical factor that is part of the causal pathway, or there was significant
missing data
Matharu et al. BMC Musculoskeletal Disorders  (2016) 17:495 Page 8 of 12
0
.2
.4
.6
.8
1
S
ur
vi
va
l p
ro
ba
bi
lit
y 
of
 th
e 
pr
im
ar
y 
hi
p 
re
pl
ac
em
en
t
0 2 4 6 8 10
Time from primary surgery to ARMD revision (years)
95% CI Metal−on−metal THR
95% CI Metal−on−metal hip resurfacing
95% CI Non metal−on−metal THR
Fig. 2 Kaplan Meier ARMD revision rate stratified by the type of primary hip replacement. ARMD = adverse reactions to metal debris;
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implant for ARMD, therefore in the illustrated Kaplan Meier plot all three subgroups ultimately reach a survival probability of zero. This
is because complete clinical data for all primary hip replacements not undergoing revision were not available for analysis in this study
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significantly higher relative risk compared to metal-on-
polyethylene and ceramic-on-polyethylene bearings. When
choosing bearing surfaces for primary THR we recommend
surgeons carefully consider the competing risks of all-cause
versus ARMD revision, the potentially devastating compli-
cation of ARMD [10, 15], and acknowledge that ARMD
revision rates in non-MoM THRs may be much higher
than we have reported due to a lack of patient surveillance
and incorrect surgeon reporting. However, our findings do
not support the use of ceramic-on-ceramic THRs of any
head size over hard-on-soft bearings if the risk of ARMD
revision is to be minimised.
Metal-on-polyethylene remains the most commonly
implanted THR bearing worldwide [18, 19]. Recently larger
head sizes have been implanted to reduce dislocation risk
and potentially reduce wear. Our observations suggest
36 mm metal-on-polyethylene bearings have a significantly
increased risk of ARMD revision compared to smaller sizes,
and an ARMD risk similar to ceramic-on-ceramic bearings.
Therefore we recommend against using 36 mm or above
metal-on-polyethylene THRs if smaller bearings can
safely be implanted. The risk of ARMD revision was
low in 28/32 mm and 36 mm ceramic-on-polyethylene
THRs suggesting it could be safe to use 36 mm femoral
heads with ceramic-on-polyethylene THRs. However,
definitive conclusions cannot be drawn given much
fewer 36 mm ceramic-on-polyethylene THRs wereimplanted compared to ceramic-on-ceramic and metal-
on-polyethylene THRs.
Mechanisms for findings
Although we have some understanding of the mechanisms
underlying ARMD development in MoM hips [12–14], we
currently do not understand why ARMD occurs in non-
MoM THRs which is extremely concerning. Some impli-
cate corrosion at modular implant junctions (femoral
head-neck junction and femoral neck-stem junction)
[20–24], with corrosion occurring due to articulating mixed
alloys, such as metal femoral heads with titanium femoral
necks [28]. Ceramic-on-ceramic bearings may develop
ARMD because of high friction causing metal debris at the
trunnion and/or other modular junctions. Large metal-on-
polyethylene bearings may be increasingly prone to wear
and corrosion at the femoral head-neck junction and/or
other modular junctions because of increased transmitted
torques from larger heads [8]. Further research is needed to
establish why ARMD develops in non-MoM THRs.
Primary surgery factors
Numerous differences existed between non-MoM and
MoM hip patients at primary surgery. These relate to the
inherent selection bias for undergoing each procedure [9]
and are factors causally related to the primary procedure,
rather than truly clinically significant differences in
ARMD revision between different bearing surfaces.
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ARMD revisions were performed significantly earlier in
non-MoM THRs compared to MoM hips. This is concern-
ing given MoM hips have high short-term failure rates
[8, 9]. We can only speculate reasons for this difference. In
addition to ARMD, non-MoM THRs had significantly
more abnormal findings at revision compared to MoM
hips. A number of these (aseptic loosening, osteolysis, im-
plant malalignment) are readily identifiable on hip radio-
graphs. The presence of such abnormalities at an early
stage of investigation may have contributed towards earlier
revision compared to MoM hips, with ARMD subse-
quently diagnosed at revision surgery. Another explanation
relates to the disease process. It is possible that ARMD due
to corrosion is more aggressive than ARMD developing
from high bearing wear, with evidence in MoM hips sup-
porting much higher failure rates in THRs compared to
hip resurfacings even with identical bearing surfaces
[14, 18]. However this requires further investigation, in-
cluding implant retrieval and histopathological analysis.
Non-MoM THRs more commonly underwent staged
revisions compared to MoM hips. As registries do not
record histopathological data we can again only speculate
an explanation for this observation. Given surgeons are
presently less aware of ARMD associated with non-MoM
THRs compared to MoM hips, and that the intra-operative
appearances of ARMD can be similar to those seen with in-
fection, it is possible that surgeons were more likely to elect
to treat failing non-MoM THRs with staged revisions rather
than in a single stage. Staged revisions in non-MoM THRs
may also have been preferable given these hips had signifi-
cantly more abnormal findings at revision which may have
required major reconstruction.
The observation that non-MoM THRs have significantly
more adverse events at revision surgery is also concerning.
This may again relate to the increased number of abnormal-
ities at revision in non-MoM hips making the surgery more
complex. Furthermore, it is expected that removing a well-
fixed corroded femoral component in non-MoM THRs is
more likely to be associated with complications, such as
fracture, compared with removing MoM hip resurfacings
which conserve femoral bone. Revision of MoM hips for
ARMD has resulted in generally poor short-term outcomes
[15]. Given that non-MoM THRs had more abnormal find-
ings and adverse events at revision surgery compared to
MoM hips, it is hypothesised they may have poor short-
term outcomes. However limited evidence is currently avail-
able [24], therefore future studies must establish outcomes
following ARMD revision in non-MoM THRs.
Strengths
Study strengths include the dataset coming from the
worlds largest arthroplasty registry which uses linked
data to ensure procedures performed at differentinstitutions were captured, with almost complete compli-
ance now reported [29]. Only small case series are presently
available [20–24], therefore our study contributes signifi-
cantly to the literature. Furthermore, by reporting on
the whole population our study is not subject to sam-
pling bias. Given the cohort size and that THR is so
common worldwide with similar bearing surfaces and
femoral head sizes implanted [3, 19], it is suspected our
findings have good external validity and generalisability,
though this requires formal validation.
Limitations
Although our study is large, it is based on observational
data therefore it is difficult to infer causality. However,
we have provided explanations for our findings based on
the literature and suggested important future research.
The risk of ARMD revision in non-MoM hips reported
here is likely to be an underestimate given surgeons may
not have been aware of this problem with these bearings,
and therefore incorrectly coded revisions using other
indications, such as infection. It is also possible some
ARMD revisions were performed but not recorded which
would also underestimate the problem [30]. Surgeons may
also have different thresholds for diagnosing ARMD at re-
vision surgery, which may influence the study findings. It
was not possible to confirm the diagnosis of ARMD histo-
pathologically using registry data. Although this is an im-
portant limitation of the present study, we recommend
future prospective studies based on non-registry cohorts
report details of their histopathological analysis and con-
firm the diagnosis of ARMD. As ARMD can be difficult to
distinguish from infection by the surgeon at the time of
revision, it is also possible that given the lack of histo-
pathological data some staged and non-staged ARMD re-
visions may actually have been for infection rather than
ARMD. Therefore the risk of ARMD revision in non-
MoM THRs may have been overestimated here. Finally, it
was not possible to access data regarding the specific hip
implant designs given this is considered sensitive informa-
tion by the NJR and manufacturers. However we recog-
nise the importance of analysing this given the significant
changes recently made to THR designs.
Conclusions
We observed a significant proportion (7.5%) of all
ARMD revisions occur in non-MoM THRs. Although
the overall risk of ARMD revision surgery in non-MoM
THRs appears low, it is increasing, and is significantly
higher in ceramic-on-ceramic THRs and in 36 mm
metal-on-polyethylene THRs. Compared to MoM hips,
non-MoM THR ARMD revisions were performed signifi-
cantly earlier and had significantly more abnormalities
and adverse events at revision surgery. ARMD associated
with non-MoM THRs may represent a significant clinical
Matharu et al. BMC Musculoskeletal Disorders  (2016) 17:495 Page 11 of 12problem that will become more apparent with time. For
primary THR we recommend using hard-on-soft bear-
ings with 28/32 mm femoral heads where possible, as
this will minimise the clinical impact of ARMD in non-
MoM hips. Further work is needed to establish whether
ARMD development in non-MoM THRs is specific to
certain implant designs.
Abbreviations
ARMD: Adverse reactions to metal debris; ASA: American Society of
Anesthesiologists; CI: confidence interval; MoM: metal-on-metal; NJR: National
Joint Registry; non-MoM THR: non-metal-on-metal total hip replacement;
THR: total hip replacement
Acknowledgements
The authors would like to thank Arthritis Research UK and The Orthopaedics
Trust who have provided one of the authors with funding to undertake this
research. We also thank the patients and staff of all the hospitals in England,
Wales and Northern Ireland who have contributed data to the National Joint
Registry. We are grateful to the Healthcare Quality Improvement Partnership
(HQIP), the NJR Research Sub-Committee and staff at the NJR Centre for
facilitating this work. The authors have conformed to the NJR’s standard protocol
for data access and publication. The views expressed represent those of
the authors and do not necessarily reflect those of the National Joint
Registry Steering Committee or the Health Quality Improvement Partnership
(HQIP) who do not vouch for how the information is presented. The Healthcare
Quality Improvement Partnership (“HQIP”) and/or the National Joint Registry
(“NJR”) take no responsibility for the accuracy, currency, reliability and
correctness of any data used or referred to in this report, nor for the accuracy,
currency, reliability and correctness of links or references to other information
sources and disclaims all warranties in relation to such data, links and references
to the maximum extent permitted by legislation.
Funding
One author (GM) received funding from Arthritis Research UK (Grant
reference number 21006) and The Orthopaedics Trust to undertake the work
contained within this manuscript. These funders had no role in the study
design, data collection, analysis and interpretation, decision to publish, or
preparation of the manuscript.
Availability of data and materials
We are unable to provide access to the dataset used for this manuscript. We
received the dataset from the National Joint Registry in pseudo-anonymised
form. This data is confidential/sensitive and not owned by the authors of the
manuscript. If the journal wishes to access the data they will need to apply
directly to the National Joint Registry as per their standard terms of data
release. Further details regarding data access can be found at (http://
www.njrcentre.org.uk/njrcentre/Research/Researchrequests/tabid/305/
Default.aspx).
Authors’ contributions
GM was involved in the design of the study, performed the data analysis
and interpretation, and drafted and revised the manuscript. HP was involved
in the design of the study, assisted with the data interpretation, and revised
the manuscript for important intellectual content. DM was involved in the
design of the study, assisted with the data interpretation, and revised the
manuscript for important intellectual content. AJ was involved in the design
of the study, assisted with the data analysis and interpretation, and revised
the manuscript for important intellectual content. All authors read and
approved the final manuscript.
Competing interests
GM has received financial support from Arthritis Research UK and The Orthopaedics
Trust to undertake research work, which includes the work presented in this
manuscript. GM has also received funding to undertake other research work from
The Royal College of Surgeons of England, and The Royal Orthopaedic Hospital Hip
Research and Education Charitable Fund.
HP is a paid consultant and speaker for Zimmer-Biomet (manufacturer of
orthopaedic implants), who have paid expenses for attending coursesand meetings. Research funding from Zimmer-Biomet and Stryker (manufacturer
of orthopaedic implants) has been paid to HP’s institution for other research work.
DM is a paid consultant and speaker for Zimmer-Biomet, who have paid
expenses for attending courses and meetings. DM receives royalties related
to an Orthopaedic knee replacement manufactured by Zimmer-Biomet.
Research funding from Zimmer-Biomet and Stryker has been been paid to DM’s
institution for other research work.
AJ is a member of the BMC Musculoskeletal Disorders journal editorial board
(Associate Editor). AJ has received consultancy, lecture fees and honoraria
from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol,
Freshfields Bruckhaus Deringer, is a member of the Data Safety and
Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals,
INC., and received consortium research grants from ROCHE. None of these
payments were related to the work presented in this manuscript.Consent for publication
Not applicable.Ethics approval and consent to participate
This study did not require ethical approval as the analysis was performed on
a national clinical dataset. However, all patients within the dataset provide
individual consent to the National Joint Registry for England, Wales, Northern
Ireland and the Isle of Man for use of their data for a number of purposes,
which includes research. A formal application was submitted to, and
approved by, the National Joint Registry to use the relevant dataset.
Author details
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford, Nuffield Orthopaedic Centre, Oxford OX3 7LD,
UK. 2Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM),
Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. 3MRC
Lifecourse Epidemiology Unit, Southampton General Hospital, University of
Southampton, Southampton SO16 6YD, UK.
Received: 27 September 2016 Accepted: 3 November 2016
References
1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip
replacement. Lancet. 2007;370:1508–19.
2. Centers for Disease Control and Prevention. Inpatient Surgery. 2015.
http://www.cdc.gov/nchs/fastats/inpatient-surgery.htm. Accessed 26
Sept 2016.
3. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and
revision hip and knee arthroplasty in the United States from 2005 to 2030.
J Bone Joint Surg Am. 2007;89:780–5.
4. Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D, Arden NK,
COASt Study Group. Future projections of total hip and knee arthroplasty in
the UK: results from the UK Clinical Practice Research Datalink. Osteoarthritis
Cartilage. 2015;23:594–600.
5. Mäkelä KT, Eskelinen A, Pulkkinen P, Paavolainen P, Remes V. Results of
3,668 primary total hip replacements for primary osteoarthritis in patients
under the age of 55 years. Acta Orthop. 2011;82:521–9.
6. Philpott A, Weston-Simons JS, Grammatopoulos G, Bejon P, Gill HS,
McLardy-Smith P, et al. Predictive outcomes of revision total hip
replacement–a consecutive series of 1176 patients with a minimum 10-year
follow-up. Maturitas. 2014;77:185–90.
7. Kwon YM, Fehring TK, Lombardi AV, Barnes CL, Cabanela ME, Jacobs JJ. Risk
stratification algorithm for management of patients with dual modular
taper total hip arthroplasty: consensus statement of the American
Association of Hip and Knee Surgeons, the American Academy of
Orthopaedic Surgeons and the Hip Society. J Arthroplasty. 2014;29:2060–4.
8. Smith AJ, Dieppe P, Vernon K, Porter M, Blom AW. National Joint Registry of
England and Wales. Failure rates of stemmed metal-on-metal hip
replacements: analysis of data from the National Joint Registry for England
and Wales. Lancet. 2012;379:1199–204.
9. Smith AJ. Dieppe P, Howard PW, Blom AW; National Joint Registry for England
and Wales. Failure rates of metal-on-metal hip resurfacings: analysis of data from
the National Joint Registry for England and Wales. Lancet. 2012;380:1759–66.
Matharu et al. BMC Musculoskeletal Disorders  (2016) 17:495 Page 12 of 1210. Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons CL,
et al. Pseudotumors associated with metal-on-metal hip resurfacings. J Bone
Joint Surg (Br). 2008;90:847–51.
11. Langton DJ, Jameson SS, Joyce TJ, Hallab NJ, Natu S, Nargol AV. Early failure of
metal-on-metal bearings in hip resurfacing and larger-diameter total hip
replacement: A consequence of excess wear. J Bone Joint Surg (Br). 2010;92:38–46.
12. Kwon YM, Glyn-Jones S, Simpson DJ, Kamali A, McLardy-Smith P, Gill HS,
et al. Analysis of wear of retrieved metal-on-metal hip resurfacing implants
revised due to pseudotumours. J Bone Joint Surg (Br). 2010;92:356–61.
13. Bolland BJ, Culliford DJ, Langton DJ, Millington JP, Arden NK, Latham JM. High
failure rates with a large-diameter hybrid metal-on-metal total hip replacement:
clinical, radiological and retrieval analysis. J Bone Joint Surg (Br). 2011;93:608–15.
14. Langton DJ, Jameson SS, Joyce TJ, Gandhi JN, Sidaginamale R, Mereddy P,
et al. Accelerating failure rate of the ASR total hip replacement. J Bone Joint
Surg (Br). 2011;93:1011–6.
15. Matharu GS, Pynsent PB, Dunlop DJ. Revision of metal-on-metal hip
replacements and resurfacings for adverse reaction to metal debris:
a systematic review of outcomes. Hip Int. 2014;24:311–20.
16. Medical and Healthcare products Regulatory Agency (MHRA). Medical
Device Alert: all metal-on-metal (MoM) hip replacements. MDA/2012/036.
2012. https://www.gov.uk/drug-device-alerts/medical-device-alert-metal-on-
metal-mom-hip-replacements-updated-advice-with-patient-follow-ups.
Accessed 26 Sept 2016.
17. U.S. Food and Drug Administration. Medical Devices. Metal-on-Metal Hip
Implants. Information for Orthopaedic Surgeons. 2013. http://www.fda.gov/
MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/
MetalonMetalHipImplants/ucm241667.htm. Accessed 26 Sept 2016.
18. National Joint Registry for England, Wales, Northern Ireland and the Isle of
Man. 12th Annual Report. 2015. http://www.njrcentre.org.uk/njrcentre/
Portals/0/Documents/England/Reports/12th%20annual%20report/
NJR%20Online%20Annual%20Report%202015.pdf. Accessed 26 Sept 2016.
19. Australian Orthopaedic Association National Joint Replacement Registry: Hip
and Knee Arthroplasty. Annual Report. 2015. https://aoanjrr.sahmri.com/
annual-reports-2015. Accessed 26 Sept 2016.
20. Cooper HJ, Urban RM, Wixson RL, Meneghini RM, Jacobs JJ. Adverse local
tissue reaction arising from corrosion at the femoral neck-body junction in
a dual-taper stem with a cobalt-chromium modular neck. J Bone Joint Surg
Am. 2013;95:865–72.
21. Molloy DO, Munir S, Jack CM, Cross MB, Walter WL, Walter Sr WK. Fretting
and corrosion in modular-neck total hip arthroplasty femoral stems. J Bone
Joint Surg Am. 2014;96:488–93.
22. Meftah M, Haleem AM, Burn MB, Smith KM, Incavo SJ. Early corrosion-related
failure of the rejuvenate modular total hip replacement. J Bone Joint Surg Am.
2014;96:481–7.
23. Whitehouse MR, Endo M, Zachara S, Nielsen TO, Greidanus NV, Masri BA,
et al. Adverse local tissue reactions in metal-on-polyethylene total hip
arthroplasty due to trunnion corrosion: the risk of misdiagnosis. Bone Joint
J. 2015;97:1024–30.
24. Plummer DR, Berger RA, Paprosky WG, Sporer SM, Jacobs JJ, Della Valle CJ.
Diagnosis and management of adverse local tissue reactions secondary to
corrosion at the head-neck junction in patients with metal on polyethylene
bearings. J Arthroplasty. 2016;31:264–8.
25. Willert HG, Buchhorn GH, Fayyazi A, Flury R, Windler M, Köster G, et al. Metal-
on-metal bearings and hypersensitivity in patients with artificial hip joints. A
clinical and histomorphological study. J Bone Joint Surg Am. 2005;87:28–36.
26. Engh Jr CA, Ho H, Engh CA. Metal-on-metal hip arthroplasty: does early
clinical outcome justify the chance of an adverse local tissue reaction?
Clin Orthop Relat Res. 2010;468:406–12.
27. National Joint Registry for England, Wales, Northern Ireland and the Isle of
Man. 7th Annual Report. 2010. http://www.njrcentre.org.uk/NjrCentre/Portals/0/
NJR%207th%20Annual%20Report%202010.pdf. Accessed 26 Sept 2016.
28. Lucas LC, Buchanan RA, Lemons JE. Investigations on the galvanic corrosion
of multialloy total hip prostheses. J Biomed Mater Res. 1981;15:731–47.
29. Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, et al.
90-day mortality after 409,096 total hip replacements for osteoarthritis, from
the National Joint Registry for England and Wales: a retrospective analysis.
Lancet. 2013;382:1097–104.
30. Sabah SA, Henckel J, Cook E, Whittaker R, Hothi H, Pappas Y, et al. Validation of
primary metal-on-metal hip arthroplasties on the National Joint Registry for
England, Wales and Northern Ireland using data from the London Implant
Retrieval Centre: a study using the NJR dataset. Bone Joint J. 2015;97:10–8.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
